Azelastine vs Bepotastine Besilate — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Histamine-1 Receptor Antagonist

Azelastine

Brand: Azelastine Hydrochloride

First FDA approval: 2009-12-01

Histamine-1 Receptor Antagonist

Bepotastine Besilate

Brand: Bepreve

First FDA approval: 2009-09-08

Lowest NADACAcquisition cost floor across all NDCs

$0.286Per unit

$13.03Per unit

Average NADACAcross all dosage forms and strengths

$0.552Up to $0.883

$17.35Up to $55.94

Generic manufacturersActive ANDA holders — FDA Orange Book

1011 total ANDAs filed

44 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$131.8MFull year

$16.6MFull year

Part D claims (CY24)Total fills, all strengths

5.1M2.4M beneficiaries

101K32K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$26Per claim, all NDCs

$165Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

7Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes10 manufacturers

Yes4 manufacturers